Pfizer (NYSE:PFE) Stock Unloaded Rep. J. French Hill

Representative J. French Hill (R-Arkansas) recently sold shares of Pfizer Inc. (NYSE:PFE). In a filing disclosed on January 23rd, the Representative disclosed that they had sold between $100,001 and $250,000 in Pfizer stock on December 31st. The trade occurred in the Representative’s “HILL 2012 TRUST” account.

Representative J. French Hill also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Kyndryl (NYSE:KD) on 12/31/2025.
• Sold $15,001 – $50,000 in shares of SFL (NYSE:SFL) on 12/31/2025.
• Sold $15,001 – $50,000 in shares of Solventum (NYSE:SOLV) on 12/31/2025.

Pfizer Price Performance

PFE stock traded up $0.33 during trading on Friday, hitting $26.43. 51,562,944 shares of the stock traded hands, compared to its average volume of 46,943,304. Pfizer Inc. has a one year low of $20.92 and a one year high of $27.69. The stock has a market cap of $150.24 billion, a price-to-earnings ratio of 15.36 and a beta of 0.47. The company has a current ratio of 1.28, a quick ratio of 0.97 and a debt-to-equity ratio of 0.62. The company has a 50 day simple moving average of $25.52 and a 200 day simple moving average of $25.03.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, beating the consensus estimate of $0.79 by $0.08. The company had revenue of $16.65 billion during the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Equities analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, January 23rd. This represents a $1.72 annualized dividend and a dividend yield of 6.5%. Pfizer’s dividend payout ratio is presently 100.00%.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of PFE. Brighton Jones LLC boosted its position in Pfizer by 1,282.4% during the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock valued at $17,677,000 after purchasing an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC boosted its position in shares of Pfizer by 12.5% in the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock worth $498,000 after purchasing an additional 2,087 shares in the last quarter. Accurate Wealth Management LLC increased its stake in shares of Pfizer by 12.5% in the 2nd quarter. Accurate Wealth Management LLC now owns 42,533 shares of the biopharmaceutical company’s stock valued at $1,096,000 after purchasing an additional 4,724 shares in the last quarter. Norden Group LLC grew its position in shares of Pfizer by 8.7% in the second quarter. Norden Group LLC now owns 35,455 shares of the biopharmaceutical company’s stock valued at $859,000 after purchasing an additional 2,828 shares during the period. Finally, Ballentine Partners LLC boosted its holdings in shares of Pfizer by 0.5% during the 2nd quarter. Ballentine Partners LLC now owns 93,228 shares of the biopharmaceutical company’s stock worth $2,260,000 after purchasing an additional 458 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. HSBC reissued a “buy” rating and set a $29.00 price target on shares of Pfizer in a report on Wednesday, December 10th. Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a report on Thursday, January 22nd. Bank of America reduced their price objective on Pfizer from $29.00 to $28.00 and set a “neutral” rating for the company in a research note on Monday, December 15th. Citigroup assumed coverage on Pfizer in a research note on Tuesday, December 2nd. They issued a “neutral” rating and a $26.00 target price for the company. Finally, The Goldman Sachs Group restated a “neutral” rating and issued a $26.00 target price on shares of Pfizer in a research report on Wednesday, November 5th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, Pfizer has an average rating of “Hold” and a consensus price target of $28.06.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: CEO Albert Bourla is doubling down on oncology with a roughly $23 billion post‑COVID investment plan, positioning Pfizer as a major growth bet on cancer therapies — a strategic pivot investors see as a multi‑year revenue driver. ‘We’ll save the world from cancer’: Inside Pfizer CEO’s $23 billion post‑COVID bet on oncology
• Positive Sentiment: Pfizer struck a non‑exclusive licensing agreement to access Novavax’s Matrix‑M adjuvant technology (reported value ~$530M), which could boost future vaccine efficacy and pipeline value. Pfizer Inks $530M Deal for Novavax Matrix‑M Adjuvant Technology
• Positive Sentiment: A bullish technical/forecast note projects upside toward ~$36.16, which can attract momentum and speculative buying. PFIZER Stock Holds Near $25.86 as Forecast Targets $36.16 Upside
• Neutral Sentiment: Pfizer is due to report Q4 and full‑year 2025 results before the market opens Feb. 3; consensus Q4 estimates cited are ~$16.9B sales and $0.57 EPS — the upcoming print is the near‑term catalyst. Should You Buy, Sell or Hold Pfizer Stock Ahead of Q4 Earnings?
• Neutral Sentiment: Zacks and other outlets report heightened retail/investor attention on PFE and provide deeper metric estimates ahead of earnings — increased search/coverage can amplify moves on the print. Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
• Neutral Sentiment: Background pieces (portfolio company lists, Wall Street metric breakdowns) add context but are unlikely to move the stock materially on their own. 7 Companies Owned by Pfizer
• Negative Sentiment: Critical commentary warns of valuation and execution risks (Seeking Alpha: “Buyer Beware”) and highlights that risks may outweigh near‑term rewards, which can pressure sentiment. Pfizer: Buyer Beware, The Risk Outweighs The Reward
• Negative Sentiment: Media coverage of past management tactics (CEO comments on extreme COVID-era measures) and notes that PFE has recently underperformed peers may feed governance/PR concerns and short‑term selling. Pfizer CEO says he used ‘emotional blackmail’ to get employees to achieve impossible goals during COVID-19 Pfizer Inc. stock underperforms Wednesday when compared to competitors

About Representative Hill

French Hill (Republican Party) is a member of the U.S. House, representing Arkansas’ 2nd Congressional District. He assumed office on January 3, 2015. His current term ends on January 3, 2027.

Hill (Republican Party) is running for re-election to the U.S. House to represent Arkansas’ 2nd Congressional District. He declared candidacy for the 2026 election.

Hill is the founder and chairman of Delta Trust & Bank. He has served as senior policy advisor to President George H.W. Bush, Deputy Assistant Secretary of the U.S. Treasury and senior advisor to Governor Mike Huckabee.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.